Allergan Upgraded to “Outperform” by Leerink Swann (AGN)
Allergan (NYSE:AGN) was upgraded by stock analysts at Leerink Swann from a “market perform” rating to an “outperform” rating in a report issued on Friday, TheFlyOnTheWall.com reports. The firm currently has a $184.00 target price on the stock. Leerink Swann’s price objective indicates a potential upside of 17.32% from the stock’s previous close.
Allergan (NYSE:AGN) traded up 3.23% on Friday, hitting $156.83. The stock had a trading volume of 3,557,933 shares. Allergan has a 52 week low of $86.95 and a 52 week high of $174.49. The stock has a 50-day moving average of $166. and a 200-day moving average of $146.. The company has a market cap of $46.607 billion and a price-to-earnings ratio of 35.74.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Monday, July 21st. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.07. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.77 billion. During the same quarter in the previous year, the company posted $1.22 earnings per share. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. On average, analysts predict that Allergan will post $5.80 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, September 5th. Investors of record on Friday, August 15th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.13%. The ex-dividend date of this dividend is Wednesday, August 13th.
A number of other firms have also recently commented on AGN. Analysts at Zacks reiterated an “outperform” rating on shares of Allergan in a research note on Tuesday, July 22nd. They now have a $205.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Allergan in a research note on Tuesday, July 22nd. They now have a $200.00 price target on the stock, up previously from $190.00. Finally, analysts at BMO Capital Markets raised their price target on shares of Allergan from $202.00 to $230.00 in a research note on Tuesday, July 22nd. They now have an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. Allergan currently has a consensus rating of “Buy” and a consensus price target of $161.83.
Allergan, Inc is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Receive News & Ratings for Allergan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.